Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 13/20 | 0.48 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | POLQ | O75417 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18794853 | 0.89 | P2RX1 (0.42) | TACR1P2RX1POLQ | |
| SCHEMBL18794873 | 0.84 | TACR1 (0.52) | TACR1CES2P2RX1L3MBTL1 | |
| SCHEMBL10426059 | 0.84 | TP53 (0.46) | CES2MAPTPOLQ | |
| SCHEMBL18794869 | 0.78 | TACR1 (0.44) | TACR1CES2P2RX1L3MBTL1 | |
| SCHEMBL5281174 | 0.74 | TACR1 (0.44) | TACR1CES2P2RX1MAPT | |
| SCHEMBL10478537 | 0.72 | TACR1 (0.45) | TACR1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL6654049 | 0.72 | TACR1 (0.43) | TACR1CES2P2RX1MAPT | |
| SCHEMBL11006983 | 0.72 | TACR1 (0.57) | TACR1CES2P2RX1MAPT | |
| SCHEMBL5543914 | 0.72 | TACR1 (0.43) | TACR1CES2P2RX1 | |
| SCHEMBL16345980 | 0.72 | CES2 (0.48) | TACR1CES2P2RX1L3MBTL1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200181067-A1 | FLUORINATED AMIDE DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS | TRILLIUM THERAPEUTICS INC. (CA) | 2020-06-11 | — | — | US | disclosed |
| US-20200181067-A1 | FLUORINATED AMIDE DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS | TRILLIUM THERAPEUTICS INC. (CA) | 2020-06-11 | — | — | US | disclosed |
| US-10604476-B2 | Fluorinated amide derivatives and their uses as therapeutic agents | TRILLIUM THERAPEUTICS INC. (CA) | 2020-03-31 | — | — | US | disclosed |
| US-20180334425-A1 | FLUORINATED AMIDE DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS | TRILLIUM THERAPEUTICS INC. (CA) | 2018-11-22 | — | — | US | disclosed |
| EP-3368509-A1 | FLUORINATED AMIDE DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS | Trillium Therapeutics Inc. (CA) | 2018-09-05 | — | — | EP | disclosed |
| WO-2017070795-A1 | FLUORINATED AMIDE DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS | TRILLIUM THERAPEUTICS INC. (CA) | 2017-05-04 | — | — | WO | disclosed |
| WO-2017070795-A1 | FLUORINATED AMIDE DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS | TRILLIUM THERAPEUTICS INC. (CA) | 2017-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180334425-A1 | FLUORINATED AMIDE DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS | GRIN2A, ACHE, BDNF | TACR1 2047/4885CES2 441/4885P2RX1 462/4885 |
| US-10604476-B2 | Fluorinated amide derivatives and their uses as therapeutic agents | GRIN2A, ACHE, BDNF | TACR1 2047/4885CES2 441/4885P2RX1 462/4885 |
| US-20200181067-A1 | FLUORINATED AMIDE DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS | GRIN2A, ACHE, BDNF | TACR1 2047/4885CES2 441/4885P2RX1 462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.